KalVista Pharmaceuticals (KALV) Posts Quarterly Earnings Results
KalVista Pharmaceuticals (NASDAQ:KALV) posted its earnings results on Thursday. The specialty pharmaceutical company reported ($0.50) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.45) by ($0.05), Bloomberg Earnings reports. The company had revenue of $1.13 million for the quarter. KalVista Pharmaceuticals had a negative return on equity of 60.42% and a negative net margin of 4,191.47%.
Shares of KalVista Pharmaceuticals (KALV) traded down $0.78 during mid-day trading on Friday, hitting $9.21. The company had a trading volume of 190,400 shares, compared to its average volume of 79,790. The company has a current ratio of 7.88, a quick ratio of 7.88 and a debt-to-equity ratio of 0.01. KalVista Pharmaceuticals has a one year low of $5.48 and a one year high of $15.80.
Separately, BTIG Research assumed coverage on KalVista Pharmaceuticals in a research report on Thursday, August 31st. They issued a “buy” rating and a $18.00 price objective on the stock.
ILLEGAL ACTIVITY NOTICE: This news story was originally published by Watch List News and is the property of of Watch List News. If you are reading this news story on another site, it was illegally copied and republished in violation of United States and international copyright legislation. The correct version of this news story can be viewed at https://www.watchlistnews.com/kalvista-pharmaceuticals-kalv-posts-quarterly-earnings-results/1766449.html.
KalVista Pharmaceuticals Company Profile
KalVista Pharmaceuticals, Inc, formerly Carbylan Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The Company has developed a portfolio of small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME).
Receive News & Ratings for KalVista Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KalVista Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.